• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by IMV Inc.

    9/22/23 4:15:14 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $IMV alert in real time by email
    S-8 POS 1 tm2326300d1_s8pos.htm S-8 POS

    As filed with the Securities and Exchange Commission on September 22, 2023

    Registration Nos. 333-225363

    333-238706

    333-239550

    333-263867

    333-268936

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    POST-EFFECTIVE AMENDMENT NO. 2 TO

    FORM S-8 REGISTRATION STATEMENT NO. 333-225363

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO

    FORM S-8 REGISTRATION STATEMENT NO. 333-238706

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO

    FORM S-8 REGISTRATION STATEMENT NO. 333-239550

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO

    FORM S-8 REGISTRATION STATEMENT NO. 333-263867

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO

    FORM S-8 REGISTRATION STATEMENT NO. 333-268936

     

    UNDER THE SECURITIES ACT OF 1933

     

    IMV INC.

    (Exact name of Registrant as specified in its charter)

     

    Canada

    (State or other jurisdiction of

    incorporation or organization)

     

    Not Applicable

    (I.R.S. Employer

    Identification No.)

     

    130 Eileen Stubbs Avenue, Suite 19

    Dartmouth, Nova Scotia, Canada

    (Address of Principal Executive Offices)

     

     

    B3B 2C4

    (Zip Code)

     

    IMV Inc. Amended Stock Option Plan

    IMV Inc. Amended Deferred Share Unit Plan

    (Full title of the plan)

     

    C T Corporation System

    28 Liberty Street

    New York, NY 10005

    (Name and address of agent for service)

     

    (212) 894-8940

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Brittany Davison

    IMV Inc.

    130 Eileen Stubbs Avenue, Suite 19

    Dartmouth, Nova Scotia B3B 2C4

    Canada

    Telephone: (902) 492-1819

    Thomas M. Rose

    Troutman Pepper Hamilton Sanders LLP

    401 9th Street, NW, Suite 1000

    Washington, DC 20004

    United States

    Telephone: (757) 687-7715

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934, as amended.

     

    Large accelerated filer  ¨ Accelerated filer  ¨
    Non-accelerated filer    x Smaller reporting company  ¨
      Emerging growth company  x

     

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act of 1933, as amended. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    IMV Inc. (the “Registrant”) is filing these Post-Effective Amendments (these “Amendments”) to those certain Registration Statements on Form S-8, Nos. 333-225363, 333-238706, 333-239550, 333-263867, and 333-268936 (as amended, if applicable, the “Registration Statements”), to terminate the offerings registered on such Registration Statements and to withdraw and remove from registration, and deregister certain securities originally registered by the Registrant pursuant to the Registration Statements. The Registrant is no longer issuing securities under the IMV Inc. Amended Stock Option Plan or the IMV Inc. Amended Deferred Share Unit Plan.

     

    In accordance with undertakings made by the Registrant in the Registration Statements to remove from registration, by means of post-effective amendment, any of the securities which had been registered for issuance but remain unsold or unissued at the termination of the offerings, the Registrant hereby terminates the effectiveness of the Registration Statements, and removes and withdraws from registration any and all such securities of the Registrant registered pursuant to the Registration Statements that remain unsold or unissued as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.

     

    -ii-

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dartmouth, Province of Nova Scotia, Canada, on September 22, 2023.

     

      IMV Inc.
       
      By: /s/ Brittany Davison
        Name: Brittany Davison
        Title: Chief Accounting Officer

     

    Pursuant to the requirements of the Securities Act, these Post-Effective Amendments to the Registration Statements have been signed by the following persons in the capacities indicated on September 22, 2023.

     

    Signature   Title
         
    /s/ Andrew Hall   Chief Executive Officer and Director
    Andrew Hall   (principal executive officer)
         
    /s/ Brittany Davison   Chief Accounting Officer and Director
    Brittany Davison   (principal financial and accounting officer)
         
    /s/ Michael P. Bailey   Chair of the Board
    Michael P. Bailey    
         
    /s/ Michael Kalos   Director
    Michael Kalos    
         
    /s/ Shabnam Kazmi   Director
    Shabnam Kazmi    
         
    /s/ Kyle Kuvalanka   Director
    Kyle Kuvalanka    
         
    /s/ Saman Maleki   Director
    Saman Maleki    
         
    /s/ Markus Warmuth   Director
    Markus Warmuth    

     

    -1-

     

     

    AUTHORIZED REPRESENTATIVE

     

    Pursuant to the requirements of Section 6(a) of the Securities Act of 1933, as amended, the undersigned has signed these Post-Effective Amendments to the Registration Statements, solely in the capacity of the duly authorized representative of IMV Inc. in the United States, on September 22, 2023.

     

      PUGLISI & ASSOCIATES
       
      By: /s/ Donald J. Puglisi
      Name: Donald J. Puglisi
      Title: Managing Director

     

     

     

    Get the next $IMV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMV

    DatePrice TargetRatingAnalyst
    9/22/2021$4.00Overweight
    Cantor Fitzgerald
    7/23/2021$14.00Overweight
    Wells Fargo
    More analyst ratings

    $IMV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IMV Receives NASDAQ Delisting Notice

    IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exercising its discretion determined to delist the Company's common shares as a result of the Company's announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order (the "Initial Order") granting the Company and its subsidiaries prote

    5/8/23 4:30:00 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    Horizon Technology Finance Announces First Quarter 2023 Financial Results

    - First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to $715 Million - - Horizon Platform Ends Quarter with Committed Backlog of $218 Million, Including $187 Million in HRZN Commitments - - Declares Regular Monthly Distributions Totaling $0.33 per Share - FARMINGTON, Conn., May 2, 2023 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ:HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and

    5/2/23 4:15:00 PM ET
    $HRZN
    $IMV
    Finance: Consumer Services
    Finance
    Pharmaceuticals and Biotechnology
    Health Care

    IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives

    IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced today that the Nova Scotia Supreme Court (the "Court") has issued an initial order (the "Initial Order") granting the Company and its subsidiaries protection under the Companies' Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the "CCAA"). The Company will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code. After a careful review of available

    5/1/23 12:30:00 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    $IMV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on IMV with a new price target

    Cantor Fitzgerald initiated coverage of IMV with a rating of Overweight and set a new price target of $4.00

    9/22/21 6:17:21 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    Wells Fargo resumed coverage on IMV with a new price target

    Wells Fargo resumed coverage of IMV with a rating of Overweight and set a new price target of $14.00

    7/23/21 7:10:01 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    $IMV
    SEC Filings

    View All

    SEC Form 15-12G filed by IMV Inc.

    15-12G - IMV Inc. (0001734768) (Filer)

    9/22/23 4:22:10 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form F-10POS filed by IMV Inc.

    F-10POS - IMV Inc. (0001734768) (Filer)

    9/22/23 4:19:43 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form F-10POS filed by IMV Inc.

    F-10POS - IMV Inc. (0001734768) (Filer)

    9/22/23 4:19:22 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    $IMV
    Leadership Updates

    Live Leadership Updates

    View All

    IMV Inc. Announces Strategic Reorganization

    Reorganization enhances organizational focus on strategic priorities Clinical update on DLBCL patients in Phase 2B VITALIZE trial to be provided in September Appointment of Dr. Saman Maleki to Board of Directors Brittany Davison promoted to Chief Accounting Officer IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and hematologic cancers, today announced a strategic reorganization together with the appointment of Dr. Saman Maleki to the Company's Board of Directors and promotion of Brittany Davison to Chief Accounting Officer. "We have m

    9/15/22 7:45:00 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    IMV Announces Annual and Special Meeting of Shareholders Voting Results

    IMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the voting results from its annual and special meeting of shareholders held on June 29, 2022 (the "Meeting"). Based on the votes received, all resolutions were accepted, including the election of directors, for whom details of the votes are as follows: Name of nominee Votes FOR % of votes FOR Votes Withheld % of votes Withheld Michael Bailey 27,525,895 99.11% 246,171 0.89% Brittany Davison 27,582,627 99.32% 189,439 0.68%

    6/30/22 7:05:00 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    IMV Appoints Andrew Hall as Chief Executive Officer

    IMV Inc. (NASDAQ:IMV, TSX:IMV), ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid tumors and blood cancers, announced today that its Board of Directors has appointed Andrew Hall to the role of Chief Executive Office and Director of the Board, effective January 1, 2022. "On behalf of the Board and the Company, I congratulate Andrew on his appointment to the Chief Executive Officer role. Over the last 5 months, Andrew has demonstrated strong leadership and refocused the Company to capitalize on its strengths in immuno-oncology, as well as a strategy designed to fully realize IMV's clear poten

    12/22/21 7:05:00 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    $IMV
    Financials

    Live finance-specific insights

    View All

    Horizon Technology Finance Announces First Quarter 2023 Financial Results

    - First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to $715 Million - - Horizon Platform Ends Quarter with Committed Backlog of $218 Million, Including $187 Million in HRZN Commitments - - Declares Regular Monthly Distributions Totaling $0.33 per Share - FARMINGTON, Conn., May 2, 2023 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ:HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and

    5/2/23 4:15:00 PM ET
    $HRZN
    $IMV
    Finance: Consumer Services
    Finance
    Pharmaceuticals and Biotechnology
    Health Care

    IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company's 2022 fourth quarter and fiscal year-end financial and operational results. Financial analysts are invited to join the conference call by registering at this link prior the call to receive their individual dial-in information. Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentations. The webcast will be

    3/9/23 7:05:00 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    IMV Inc. Announces Third Quarter 2022 Financial and Operational Results

    IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the third quarter ended September 30, 2022. "IMV worked diligently to deliver on our clinical goals in the third quarter. We restructured the business to facilitate the achievement of these objectives and remain on track to present meaningful clinical data early next year," said Andrew Hall, Chief Executive Officer of IMV. "We expect 2023 to be a potentially transformative year for IMV, w

    11/10/22 4:05:00 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    $IMV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by IMV Inc.

    SC 13G - IMV Inc. (0001734768) (Subject)

    2/14/23 12:57:14 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form SC 13G/A filed by IMV Inc. (Amendment)

    SC 13G/A - IMV Inc. (0001734768) (Subject)

    2/3/23 12:06:43 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form SC 13G/A filed by IMV Inc. (Amendment)

    SC 13G/A - IMV Inc. (0001734768) (Subject)

    7/21/21 2:03:29 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care